Peptide-based immunotherapy of autoimmunity: A path of puzzles, paradoxes and possibilities

Immunology

Volumn 104, Issue 4, 2001, Pages 367-376

  Anderton, Stephen M ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; EPITOPE; GLATIRAMER; PEPTIDE DERIVATIVE;

ALLERGIC ENCEPHALOMYELITIS; ANAPHYLAXIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T LYMPHOCYTE;

APOPTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL;

EID: 0035675871     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01324.x     Document Type: Review

References (103)

1. Tickling the TCR. Selective T-cell functions stimulated by altered peptide ligands
2. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand
3. Separation of T helper 1 clone cytolysis from proliferation and lymphokine production using analogue peptides
4. Antigen analogue-major histocompatibility complexes act as antagonists of the T cell receptor
5. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues
6. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology
7. The dynamics of T cell receptor signaling: Complex orchestration and the key roles of tempo and cooperation
8. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis
9. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis
10. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice
11. T cell determinant structure of myelin basic protein in B10.PL, SJL/J, and their F1S
12. Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein
13. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy
14. Cross-reactive antigen recognition by an encephalitogenic T cell receptor. Implications for T cell biology and autoimmunity
15. Fine specificity of the myelin-reactive T cell repertoire: Implications for TCR antagonism in autoimmunity
16. An autoantigenic T cell epitope forms unstable complexes with class II MHC. A novel route for escape from tolerance induction
17. Quantitative analysis of peptides from myelin basic protein binding to the MHC class II protein, I-Au, which confers susceptibility to experimental allergic encephalomyelitis
18. A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11
19. Evidence that the autoimmune antigen myelin basic protein (MBP) Ac1-9 binds towards one end of the major histocompatibility complex (MHC) cleft
20. Negative selection during the peripheral immune response to antigen
21. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis
22. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: More than blocking alone
23. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis
24. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire
25. Imogen 38: A novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient
26. Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes
27. Peptide analogues to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis
28. Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogues
29. Single amino acid analogues of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis
30. Oral administration of a dual analogue of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice
31. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand
32. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99
33. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99)
34. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells
35. + T-cell subsets in autoimmunity
36. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease
37. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease
38. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells
39. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
40. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy
41. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis
42. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens
43. Autopathogenic T helper cell type 1 (Th1) and protective Th2 clones differ in their recognition of the autoantigenic peptide of myelin proteolipid protein
44. + T cells into Th1 and Th2 subsets
45. + T cells by antigenic peptides altered for TCR binding
46. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
47. + T cell responses: The alternative approaches
48. + T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model
49. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production
50. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
51. Immunological aspects of demyelinating diseases
52. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1
53. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
54. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis
55. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1
56. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
57. Copolymer 1 inhibits experimental autoimmune uveoretinitis
58. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones
59. Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells
60. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention
61. Low avidity recognition of self-antigen by T cells permits escape from central tolerance
62. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
63. Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
64. Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis
65. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
66. Mature T lymphocyte apoptosis - Immune regulation in a dynamic and unpredictable antigenic environment
67. Induction of apoptosis and T helper 2 (Th2) responses correlates with peptide affinity for the major histocompatibility complex in self-reactive T cell receptor transgenic mice
68. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms
69. Antigen-specific elimination of T cells induced by oligomerized hemagglutinin (HA) 306-318
70. Selective induction of apoptosis in mature T lymphocytes by variant T cell receptor ligands
71. A kinetic basis for T cell receptor repertoire selection during an immune response
72. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes
73. A very high level of crossreactivity is an essential feature of the T-cell receptor
74. Selection of the T cell repertoire
75. Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus
76. Tuning T cell activation threshold and effector function with cross-reactive peptide ligands
77. Immunological unresponsiveness
78. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity
79. Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice - Implications for autoimmunity
80. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin
81. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
82. + T cells precedes the development of tolerance in vivo
83. Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide
84. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes
85. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis
86. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope
87. Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis
88. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes
89. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23)
90. Mechanisms of central and peripheral T-cell tolerance: Lessons from experimental models of multiple sclerosis
91. Myasthenia gravis
92. Autoimmune thyroid disease
93. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor
94. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
95. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: Mechanisms of selection of the self-reactive repertoire
96. Antigen-driven tissue-specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse
97. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: A role for IL-10
98. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice
99. Regulatory T cells and inflammatory bowel disease
100. An unexpected version of horror autotoxicus: Anaphylactic shock to a self-peptide
101. Dominance and crypticity of T cell antigenic determinants
102. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis
103. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase